Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Support holding ⢠Choppy consolidation ⢠Overhead resistance Support Level: $33.22-$33.26 Resistance Level: $35.90-$35.96 Over the last month, PHVS is mildly constructive but choppy, with support holding in the low-$33 area and upside capped near $35.96.
Sentiment & News
Key News Insights: ⢠NDA Accepted ⢠Scientific Support ⢠Insider Sale PHVS is gaining momentum as the FDA accepts its hereditary angioedema NDA and supportive science boosts the thesis, but a recent insider sale after a sharp run signals possible near-term profit-taking.
AI Summary
PHVS has moved from a speculative biotech story to a more de-risked late-stage regulatory asset with FDA NDA acceptance, a set PDUFA date, and funding into 2028, but it remains a pre-revenue, binary event-driven name where approval and upcoming CHAPTER-3 data are the key catalysts for upside.
Description
Pharvaris N.V. is a clinicalâstage biopharmaceutical company developing treatments for rare diseases, with a primary program targeting hereditary angioedema (HAE). Its lead smallâmolecule bradykinin B2âreceptor antagonist is in Phase II, and the pipeline includes both an onâdemand oral soft capsule in Phase II and an extendedârelease prophylactic tablet in early clinical testing. The company operates in the Netherlands, Switzerland and the United States and was founded in 2015 with headquarters in Leiden, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 1 | Apr 8 | PHVS | Pharvaris N.V. | Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility. | Closed | -6.4% |